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Can Drug Screening Lead to Candidate Therapies for Testing
in Diabetic Neuropathy?
ANDREA M. VINCENT and EVA L. FELDMAN
ABSTRACT
A key mechanism of dorsal root ganglia (DRG) neuron injury in high glucose is mitochondrial overload lead-
ing to oxidative stress. We screened selected compounds for the ability to prevent hyperglycemia-induced mi-
tochondrial superoxide in primary sensory DRG neurons. Twenty five out of 1,040 compounds decreased both
mitochondrial superoxide and subsequent neuronal injury. These data both validate our screening strategy
and indicate further mechanistic evaluation of drug hits and related compounds. Such studies may lead to the
design of rational therapeutic approaches for this severe complication of diabetes. Antioxid. Redox Signal. 10,
387–393.
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DRUG SCREENING AS A TOOL 
FOR DISCOVERY
DRUG AND SMALL MOLECULE SCREENING is a developing fieldof discovery science for rapid translational research. A
PubMed search on 6/16/07 combining “high-throughput” and
“primary” for relevant cell-based assays yielded 608 hits of
which 82% were published in the last 5 years. These assays are
used for both drug development and diagnostic purposes (3, 29).
Whereas compound set screens generate large amounts of data,
the translation of screening data to clinical utility requires care-
ful follow-up studies and broad, intensive literature searching.
OXIDATIVE STRESS IN 
DIABETIC NEUROPATHY
Diabetic neuropathy is a common and increasingly prevalent
disorder that is responsible for significant patient morbidity and
healthcare burden (17, 26). While many mechanisms contribut-
ing to the development of the disease are known, and many drugs
have progressed to clinical trials, there is still no effective FDA-
approved treatment for diabetic neuropathy. The mechanisms
leading to sensory neuron injury in diabetic neuropathy converge
upon the development of oxidative stress (1, 23), although de-
creased neurotrophic support and cellular inflammation also con-
tribute to the disorder (2, 27). Because an array of nerve func-
tions is dysregulated in diabetic neuropathy, testing the efficacy
of therapeutic strategies is difficult in clinical and experimental
diabetes. Primary testing still requires an in vitro system to as-
sess single therapeutic targets alone and in combination. A ma-
jor contributor to neuronal injury in diabetes is glucose-induced
mitochondrial oxidative stress (14, 20, 25). We recently found
strong evidence to support this mechanism in dorsal root ganglia
(DRG) neurons. Overexpression of the mitochondrial antioxidant
enzyme MnSOD prevents glucose-induced DRG neuron injury
(24). Recognizing the importance of this pathway, the Juvenile
Diabetes Research Foundation (JDRF), in conjunction with Na-
tional Institute of Health-National Institute of Diabetes and Di-
gestive and Kidney Diseases (NIH-NIDDK), funded a program
to screen a panel of 1040 selected compounds for the prevention
of mitochondrial oxidative stress in cell types relevant to diabetic
neuropathy. A document containing a summary of these assays
and the outcomes is available online (http://www.t1diabetes.
nih.gov/investigator/Drug-ScreeningSummary-Final.doc).
AN INITIAL SCREEN FOR
MITOCHONDRIAL OXIDATIVE STRESS
In response to the JDRF/NIH-NIDDK program, we applied
our assay of mitochondrial superoxide (MitoSOX) generation
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in embryonic rat primary DRG neurons (25). Exposure to 20
mM added glucose increases MitoSOX oxidation in DRG
neurons (Fig. 1A). Mean fluorescence is close to zero in un-
treated controls, and the fluorescence increases significantly
at every time-point from 1 to 5 h. MitoSOX oxidation peaks
at 2 h following the application of glucose. To confirm that
MitoSOX is measuring mitochondrial ROS, mitochondrial
function was increased using creatine (2 mM) or decreased
by the uncoupling agent FCCP (10 M) (Fig. 1B). We pre-
viously demonstrated that 25 mM FCCP produces robust mi-
tochondrial depolarization that decreases ROS in the pres-
ence of high glucose (22). Now we find that mild uncoupling
decreases MitoSOX oxidation, demonstrating that MitoSOX
is indeed oxidized by mitochondrial generation of ROS. The
localization of MitoSOX oxidation is illustrated in the rep-
resentative images in Fig. 1C. Red MitoSOX fluorescence is
weak in control DRG neurons, but markedly increased after
1 h glucose exposure. We identified 30 compounds that de-
creased glucose-induced mitochondrial superoxide at 1 M
concentration at 1 h (Table 1). A dose curve in the range 100
M to 1.28 nM with 5 dilutions was performed for each of
the 30 compounds. The lowest concentration of compound
that significantly (p  0.05) decreased mitochondrial super-
oxide compared with glucose alone is reported in Table 1 as
the effective concentration.
A SECONDARY OXIDATIVE 
STRESS ASSAY VALIDATES 
PRIMARY SCREENING
To confirm that the 30 compounds decreased oxidative stress
leading to cellular oxidative modifications, a repeat set of sam-
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FIG. 1. Assessment of oxidative stress in DRG neurons. (A) A time-course of MitoSOX oxidation indicates rapid and sus-
tained mitochondrial superoxide following the application of 20 mM glucose. Each time point showed increased mitochondrial
superoxide compared to untreated control neurons, *p  0.01. (B) To confirm the mitochondrial source of ROS, DRG neurons
were exposed to 2 mM creatine, 10 M FCCP, 20 mM glucose, or a combination for 1 h. MitoSOX oxidation at 1 h reveals that
creatine that increases mitochondrial activity increases MitoSOX oxidation compared to control (*p  0.01). Mild mitochondr-
ial uncoupling using FCCP slightly decreases basal MitoSOX oxidation and significantly decreases glucose-induced and crea-
tine-induced MitoSOX oxidation (p  0.01 compared to glucose or creatine only). (C) Representative MitoSOX oxidation is
examined by confocal microscopy. DRG neurons were loaded with MitoSOX (red) and Mitotracker (green) for 15 min, then
fixed and mounted for microscopy. In the overlay, yellow fluorescence indicates mitochondrial superoxide. The red signal gen-
erally is stronger than the green, so overwhelms the yellow overlay color. (D) Representative nitrotyrosine immunohistochem-
istry is examined by confocal microscopy. Red nitrotyrosine labeling increased 5 h after the application of 20 mM glucose. A
drug that prevented MitoSOX oxidation (“drug hit”) also prevented glucose-induced nitrotyrosine. A drug that did not prevent
MitoSOX oxidation (“nonprotective drug”) did not prevent glucose-induced nitrotyrosine. (E) All of the compounds that de-
creased MitoSOX oxidation were assessed at 2 M for the ability to decrease nitrotyrosine measured in the fluorescence plate
reader. Each blue bar represents a single test of one drug. All of the drugs assessed in this secondary screen decreased glucose-
induced nitrotyrosine.
ples treated with drug, then glucose, was prepared. In this and
all subsequent experiments, the drugs were applied at 2 M. A
single dose was selected to simplify the assay and maintain the
screening format. We anticipated that having identified drug
hits, we would more easily observe a response using 2 M
rather than 1 M. After 5 h glucose treatment, the DRG neu-
rons were fixed, and then immunolabeled for nitrotyrosine. The
immunolabel was measured on the fluorescence plate reader
(Fig. 1E). All of the drugs that decreased MitoSOX oxidation
also decreased nitrotyrosine, compared to glucose alone. A sep-
arate set of DRG neurons was cultured on glass coverslips, and
the localization and relative fluorescence intensity was exam-
ined by confocal microscopy. Representative images of ni-
trotyrosine labeling in these cultures are shown in Fig. 1D. A
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TABLE 1. RANKING OF DRG NEURON PROTECTIVE COMPOUNDS
Known
mechanisms of Effective
Rank Compound Typical application action concentration*
10 Cetylpyridinium Cl Anti-infective 4 M
10 Phenylmercuric Antifungal 4 M
acetate
20 Ergocalciferol Antirachitic vitamin Vitamin D2 1.28 nM
20 Benazepril HCl ACE inhibitor, 20 M
20 Crustecdysdone Insect molting 0.8 M
hormone
30 Gossypol Antispermatigenic, Causes conf D in 20 M
antineoplastic, antiHIV BCl2, release cyto c
30 Levonordefrin Vasoconstrictor 1.28 nM
30 Clemastine Antihistamine Potent inhibitor of 32 nM
K channels
30 Carnitine HCl Antihyperlipoprotein Prevents ox stress 0.8 M
emic and PCD in
neurodeg dis
40 Prothionamide Antibacterial Dehydrogenease 0.8 M
inhibitor
40 Betamipron Sweetener 0.8 M
40 isoproterenol HCl Bronchodilator 0.16 M
40 Roxarsone Antibacterial 0.8 M
50 Caffeine CNS stimulant 0.8 M
50 Meclizine HCl Antiemetic 6.4 nM
50 Fenofibrate Antihyperlipidemic ALS hit, PPARa 0.8 M
agonist, activates
MAPK
50 3-Aminopropanesulfonic Antibacterial GABA Agonist 0.8 M
acid
50 Aminohippuric acid Renal function 0.8 M
diagnosis
50 Morin P450 & ATPase 0.16 M
inhibitor
60 Bepridil HCl Antiarrhythmic 4 M
60 Paclitaxel Antineoplastic 0.16 M
60 Gentamicin HCl Antibacterial 20 M
60 Minoxidil Antihypertensive Activates ATP-dep 0.8 M
K channels
60 Piperazine Antihelmintic ALS hit, blocks ion 6.4 nM
flux, can increase
memb potl
70 SNAP Muscle relaxant NO donor 0.8 M
70 Praziquantel Antihelmintic 32 nM
70 Cefuorxamine Na Antibacterial 6.4 nM
70 Carbenoxolone Na Antiinflammatory, 0.16 M
antisecretory
90 Atenolol Beta adregnergic 0.8 M
blocker
90 Suprofen Antiinflammatory NSAID—inhibits 0.8 M
P450
*Lowest concentration that prevented glucose-induced DRG MitoSOX oxidation
drug that did not prevent MitoSOX oxidation is presented for
comparison. This nonprotective drug did not prevent glucose-
induced increase in nitrotyrosine (Fig. 1D). Taken together, Fig.
1 demonstrates that MitoSOX is a robust, specific assay for mi-
tochondrial superoxide that is sensitive enough for drug screen-
ing. Confirmation that MitoSOX oxidation is related to cellu-





Next, the ability to prevent DRG neuron injury was as-
sessed using the TUNEL assay with each of the 30 primary
drug hits tested at 2 M. Compounds were then ranked ac-
cording to the ability to prevent DRG neuron injury (Table
1). Toxic compounds were given the lowest rank of 10. Com-
pounds that neither increased nor decreased glucose-induced
DRG neuron death were scored 20. For every subsequent de-
crease in TUNEL staining, the rank score was increased by
10. The initial decrease of 10% in TUNEL compared with
glucose scored 30. Further decreases of 5% in TUNEL were
scored in increments of 10. Thus, at 2 M, suprofen and
atenolol were the most protective at the 2 M concentration,
producing a 40% decrease in glucose-induced TUNEL posi-
tivity, which is similar to untreated control. Note that this is
not necessarily the maximum protection, since the drugs were
screened at a single low concentration (2 M). The data dem-
onstrate that almost all compounds which prevent mitochon-
drial oxidative stress also prevent cell death. This supports
the significance of mitochondrial superoxide in neuronal hy-
perglycemic injury as we have previously proposed (14, 20,
25) and further underscores the importance of preventing
DRG neuron mitochondrial oxidative injury in diabetes 
patients.
SUPPORTING EVIDENCE FOR THE ROLE
OF MITOCHONDRIAL STRESS IN
HYPERGLYCEMIC INJURY
Three compounds prevented mitochondrial oxidative stress
but were not protective. These compounds, cetylpyridinium
Cl, phenylmercuric acetate, and ergocalciferol, likely directly
blocked mitochondrial function. It is important, therefore,
that compounds identified in a single screening assay should
undergo secondary or related assays prior to translation to ex-
perimental animal or clinical trials. Other mild mitochondr-
ial inhibitors such as gossypol and SNAP both decreased ox-
idative stress and improved DRG neuron survival in our
short-term assay. These data further support our hypothesis
that glucose-induced overactivation of mitochondria pro-
duces oxidative injury and leads to diabetic neuropathy (22,
25). However, rational consideration of the likely mechanism
of action excludes them from further exploration as experi-
mental therapeutics.
THE SCREEN IDENTIFIES POTENTIAL
NEW THERAPEUTIC AGENTS FOR
DIABETIC NEUROPATHY
Reasonable mechanisms of action are inferred from previous
studies for all of the other drug “hits” from this screen. Several
of them suggest promising avenues for the development of new
therapies against hyperglycemic injury. Particular compounds,
notably morin (4, 8), carnitine (4), and carbenoxolone (6) di-
rectly act as antioxidants, further supporting our contention that
preventing oxidative stress is an important adjunct therapy for
diabetic neuropathy. We are intrigued by the identification of
both anti-inflammatory compounds and compounds that alter
ion channel function. Inflammatory mechanisms are receiving
increasing interest in the development of diabetic neuropathy.
Largely, studies suggest that inflammation secondary to reduced
blood flow exacerbates diabetic neuropathy (13, 27). The drug
screen suggests an additional beneficial effect of anti-inflam-
matory agents by directly impacting upon the survival of DRG
neurons. In a related screen using a model of amyotrophic lat-
eral sclerosis with motor neurons exposed to glutamate, many
different ion channel inhibitors prevented programmed cell
death (19). Taken with the current data, we infer that ion chan-
nel inhibition in neurons can broadly prevent toxin-induced in-
jury. Probably the neuronal insults cause loss of ion channel
regulation and the inhibitors permit conservation of energy sta-
tus in the face of toxin-induced stress.
FENOFIBRATE AS AN 
EXPERIMENTAL THERAPEUTIC
The most interesting compound is fenofibrate. This com-
pound is a PPAR agonist used to decrease hyperlipidemia (18,
28). In mice with hereditary fatty liver disease, fenofibrate de-
creased liver triglycerides and improved antioxidant status (5).
For this reason, fenofibrate is used in type 2 diabetic patients.
Several recent studies demonstrated additional benefits from us-
ing this compound. Plasma inflammatory mediators are elevated
in patients with impaired glucose tolerance, but short-term ther-
apy with fenofibrate decreased both cytokines and C-reactive
protein (11). In a genetic model of type 2 diabetes, the db/db
mouse, fenofibrate improved all the signs and symptoms of both
diabetes and diabetic nephropathy with decreased hyper-
glycemia and hyperinsulinemia and decreased urinary albumin
excretion (12). Furthermore, fenofibrate prevented excess col-
lagen I deposition by cultured mesangial cells (12). A recent
review highlighted the pleiotropic benefits against type 2 dia-
betes and resulting nephropathy (18), and another suggested that
fibrates protect against diabetic cardiovascular disease as well
as nephropathy and retinopathy (28). We now present prelimi-
nary evidence that fibrates may directly prevent neuronal in-
jury in hyperglycemia in addition to the effects demonstrated
by others. This drug demands further experimental testing and
we are initiating a trial of fenofibrate in a mouse model of type
1 diabetes. Generally, fibrates are well tolerated and safe in
combination therapies (28), suggesting that this could be a pow-
erful component in a cocktail targeting the multiple mechanisms
leading to diabetes complications.
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DATA VALIDATION IN ADULT 
DRG NEURONS
Adult DRG neurons are a better accepted model for assess-
ment of the mechanisms of diabetic neuropathy for two major
reasons: [a] they are mature, unlike embryonic cultures, and di-
abetic neuropathy occurs in adult patients; [b] they may be cul-
tured in lower basal concentrations of glucose, so a hyper-
glycemic insult is more representative of the in vivo
environment. Therefore, we cultured adult rat DRG neurons in
96-well plates to confirm our positive results. First, we per-
formed the MitoSOX oxidation analysis. The glucose-induced
increase in MitoSOX fluorescence at 1 h in adult DRG neurons
was 10-fold lower compared to embryonic DRG neurons (Fig.
2A). This may be related to a lower cell density on the plate,
determined visually, or may be a result of lower basal glucose.
Nevertheless, the increase was highly significant and repro-
ducible. Fenofibrate (2 M) treatment was combined with ex-
posure to 20 mM added glucose (total 25.7 mM glucose) for 1
h. Fenofibrate was added at the same time (Fen-Co) or as a 3
h pretreatment (Fen-Pre) relative to 20 mM added glucose. Both
co-treatment and pretreatment with fenofibrate significantly de-
creased glucose-induced mitochondrial superoxide generation.
The 3 h pretreatment provided greater protection, suggesting
that DRG neurons respond to fenofibrate with a mechanism that
decreases susceptibility to high glucose, such as new gene ex-
pression or post-translational modification.
Next, we assessed adult DRG neuron injury using the
TUNEL assay (Fig. 2B). In this experiment, fenofibrate (2 M)
was applied alone (Fen), as a 3 h pretreatment (Fen-Pre), a co-
treatment (Fen-Co), or 1 h subsequent to 20 mM added glucose
(Fen-Post). DRG neuron injury following exposure to 20 mM
added glucose (total 25.7 mM glucose) was similar to the in-
jury seen in embryonic DRG neurons. This result strengthens
our case for the use of embryonic DRG in our screening strate-
gies despite the high basal glucose. We previously maintained
that fluctuations in glycemia injures neurons and is an impor-
tant consideration for clinical management of diabetes (20). All
fenofibrate treatment paradigms significantly decreased glu-
cose-induced DRG neuron injury, with the greatest protection
with earlier application of the drug. The protection observed
with a 1 h post-treatment strongly suggests that fenofibrate
functions as a direct antioxidant in this system.
IMPLICATIONS OF THE STUDY
Drug screening using primary DRG neuron cultures led us
to begin further in vitro and in vivo assessment of fenofibrate
as an experimental therapeutic for diabetic neuropathy. In ad-
dition, carnitine (9) and bepridil have received recent attention
in experimental diabetes. Several of these compounds may
merit further study. We are convinced that certain of these com-
pounds, potentially in combination with conventional antioxi-
dant therapy (25), will produce innovative clinical approaches
to prevent or treat diabetic neuropathy. These data validate the
use of MitoSOX as a drug screening strategy including and the
use of embryonic DRG neurons that can be obtained in suffi-
cient numbers and purity for the screening protocol.
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ABBREVIATIONS
DRG, dorsal root ganglia; FUDR, fluoro-2-deoxyuridine;
NGF, nerve growth factor; TUNEL, terminal deoxy-UTP nick-
end labeling.
APPENDIX
Embryonic DRG cultures for drug screening
Timed pregnant rats are purchased from Charles River Laboratories.
All rodent care and use is approved and regulated by the Unit for Lab-
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FIG. 2. Validation of results using adult DRG neurons. (A)
MitoSOX oxidation was assessed after 1 h exposure to 20 mM
glucose. Fenofibrate (2 M) was applied 3 h prior to (Fen-Pre),
or at the same time as (Fen-Co) the glucose. *p  0.01 compared
with glucose only; p  0.05 compared to pretreatment. (B)
DRG neuron injury was assessed by TUNEL 24 h after exposure
to 20 mM glucose and/or fenofibrate. An additional post-treat-
ment paradigm (Fen-Post) was included where fenofibrate was
applied 1 h subsequent to glucose. *p  0.05 compared to un-
treated control; p  0.01 compared to glucose only treatment.
oratory Animal Medicine at the University of Michigan. DRG are har-
vested from embryonic day 15 Sprague–Dawley rats, dissociated in 1%
trypsin, then cultured on tissue culture plates in growth media. Black-
walled 96-well plates (Falcon Labware, BD Biosciences, San Jose, CA)
are coated with rat tail type 1 collagen (Sigma, St Louis, MO) prior to
applying DRG neurons. Immediately prior to use, collagen is dissolved
in sterile 1 M acetic acid to 10 mg/ml, then diluted in sterile distilled
water to 1 mg/ml, spread in a thin layer on the culture plate, and al-
lowed to air dry in a laminar flow hood. All culture reagents are from
Gibco (Grand Island, NY) unless stated otherwise. Growth media is pre-
pared using Neurobasal medium supplemented with 1  B-27 additives,
50 ng/ml NGF (Harlan Bioscience, Indianapolis, IN), 40 M FUDR
(Sigma), and 1,000 U/ml penicillin/streptomycin/neomycin solution. Ini-
tial plating medium contains 2 M glutamine. Fifteen embryos are used
to seed 1 96-well plate. DRG neurons are re-fed after 24 h in fresh
media containing all additives except glutamine. On day 2, cells are
rinsed, then re-fed using treatment media (Neurobasal media containing
4 ng/ml selenium, 4 ng/ml hydrocortisone, 0.01 mg/ml transferrin, 3
ng/ml -estradiol, 50 ng/ml NGF, 40 M FUDR, and 1,000 U/ml peni-
cillin/streptomycin/neomycin. Experiments are performed on DRG neu-
rons on the third day in culture in the absence of B-27 additives. Neu-
robasal medium contains a basal 25 mM glucose that is essential for
DRG neuron culture (7, 14–16). A decrease of 5 mM glucose leads to
increased DRG neuron death, while increasing the glucose concentra-
tion above 35 mM induces hyperglycemic stress, ROS, and cell injury
(14). To produce a hyperglycemic insult, 20 mM additional glucose
(yielding a total 45 mM glucose) is added to the media for the period
specified in individual experiments. This glucose load is rather higher
than may be achieved except in extreme cases of uncontrolled diabetes.
However, the basal 25 mM glucose is required for these cultures in vitro.
We and others have demonstrated that it is acute changes in glucose
load that produce injury, more than sustained elevated glucose (10, 20),
making this a useful model for drug screening (25). The glucose con-
centrations used do not produce increased stress and injury due to os-
motic effects, as demonstrated in previous studies (20, 25).
Adult DRG neuron cultures
DRG are collected from the euthanized adult female rat and disso-
ciated in 0.2% collagenase for 30 min, followed by 1% trypsin for 15
min. Cells are resuspended in adult neuron growth media, then seeded
on collagen-coated plates as described for embryonic DRG. All subse-
quent experimental procedures are the same as for embryonic cultures
except for the substitution of adult growth media (DMEM:F-10, 50:50,
1  B27 additives, 40 M FUDR, and 1,000 U/ml penicillin/strepto-
mycin/neomycin. In this media the basal glucose concentration is 5.7
mM. To produce a hyperglycemic insult, 20 mM additional glucose
(yielding a total 25.7 mM glucose) is added to the media for the period
specified in individual experiments.
Measurement of reactive oxygen species
MitoSOX (Molecular Probes, Eugene, OR) is a cell-permeable probe
that accumulates specifically in mitochondria and becomes fluorescent
following oxidation by superoxide. MitoSOX is dissolved in DMSO
immediately prior to use, then applied to DRG neurons at a final con-
centration of 4 M with DMSO diluted to 0.1%. After 15 min, me-
dia is removed and replaced with 100 L Hepes-buffered saline solu-
tion (HBSS: 10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2); then red fluorescence is read at 485 nm exci-
tation and 590 nm emission (Fluoroskan Ascent II plate reader, Lab-
Systems, Helsinki).
Fragmentation of genomic DNA
TdT mediated dUTP-biotin nick end labeling (TUNEL) staining is
used to detect programmed cell death in DRG neurons. DRG neurons
are fixed in 4% paraformaldehyde prior to staining. Samples are la-
beled with digoxygenin-dUTP and then stained with horseradish per-
oxidase-conjugated anti-digoxygenin antibody using a kit according to
the manufacturer’s instructions (Intergen, Gaithersburg, MD). We pre-
viously demonstrated that the TUNEL assay is a reliable and repro-
ducible indicator of neuronal injury (19, 21, 25).
Nitrotyrosine immunohistochemistry
DRG neurons were treated as described, then fixed in 4% parafor-
maldehyde in 0.1 M phosphate buffered saline solution (PBS) for 5 min.
Primary antibody was anti-nitrotyrosine 244 (Upstate Biologicals, Lake
Placid, NY) at 10 g/ml final concentration in 0.1 M PBS containing
1% Triton X100 and 5% goat serum for 16 h at 4°C. Cells were washed
for 3 10 min in PBS, then goat anti-rabbit-AlexaFluor 594 secondary
antibody (Molecular Probes) was applied for 1 h at room temperature.
Secondary was diluted 1:1,000 in 0.1 M PBS containing 1% Triton
X100 and 5% goat serum. After 3x 10 min washes in PBS, fluores-
cence was assessed by reading on the fluorescent plate reader at 485
ex, 590 em, or coverslipped and examined on a Nikon Diaphot 200 in-
verted fluorescent microscope (Nikon, Melville, NY). Digital images
were captured with a Hamamatsu ORCA ER camera (Hamamatsu,
Bridgewater, NJ).
Statistical analysis
All experimental samples are assayed on three separate occasions with
two–three replicates in each assay. For determination of percent posi-
tive in TUNEL assay, at least 10 fields, each containing at least 10 neu-
rons, are counted per replicate assay. The total numbers of cells in each
field are compared between experimental and control conditions to con-
firm that the numbers are equivalent. This is important to consider, since
if dying cells detach from the dish, the data are skewed. The mean and
standard error for the three repeats are calculated. Statistical significance
is determined using ANOVA with 95% confidence intervals.
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